Assessment of ADRs on ANAs: A Study Done By Indian Pharm D Students

The clinical pharmacist in oncology care team has a crucial role in patient care through improving use of chemotherapy and other high alert medications. As part of multidisciplinary team, clinical pharmacist needs to assure safe, effective, cost-effective and more patient-oriented drug therapy. Adverse Drug Reactions are noxious and unintended death causing factor in cancer treatment. Antineoplastic drugs were mostly prescribed for cancer patients, who has greater suspectability towards ADRs. Along with other onco healthcare professionals, clinical pharmacist intervention in the treatment planning of the cancer patients, can identify, detect, assess, educate, monitor, minimize, prevent & manage the ANAs induced ADRs by supportive antidote therapy & palliative care, that can produce a impact by minimize economic burden & improving QOL, which can be sudden & significant, the latter can be particularly important to patients who want to live as normally as possible after diagnosis. The p value of the current study was found to be 0.006 (highly significant). & Chi-square value was 18.04, which shows a directly proportional association b/w ADR probability scores & stages of cancer.

Autorentext

Dr. JOEL THOMAS, Pharm D:Padmavathi College of Pharmacy,Dharmapuri & Gov. Head Quarters Hospital,Krishnagiri na Dr. MGR Medical University. Feito Residência de Farmácia Clínica: Cardiac,Nephro,Neuro,Paediatics & Orthopaedics nos Hospitais Sagar e Oncologia nos Hospitais HCG, Banglore. Farmacêutico indiano registado na KSPC. S/o Thomas AP & Annies Thomas